274 related articles for article (PubMed ID: 29530935)
1. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
[No Abstract] [Full Text] [Related]
2. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
Sperinde J; Huang W; Vehtari A; Chenna A; Kellokumpu-Lehtinen PL; Winslow J; Bono P; Lie YS; Petropoulos CJ; Weidler J; Joensuu H
Clin Cancer Res; 2018 Jul; 24(13):3046-3052. PubMed ID: 29535130
[No Abstract] [Full Text] [Related]
3. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
Duchnowska R; Sperinde J; Chenna A; Haddad M; Paquet A; Lie Y; Weidler JM; Huang W; Winslow J; Jankowski T; Czartoryska-Arłukowicz B; Wysocki PJ; Foszczyńska-Kłoda M; Radecka B; Litwiniuk MM; Zok J; Wiśniewski M; Zuziak D; Biernat W; Jassem J
Clin Cancer Res; 2014 May; 20(10):2805-13. PubMed ID: 24668646
[TBL] [Abstract][Full Text] [Related]
4. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
6. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
[TBL] [Abstract][Full Text] [Related]
7. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
Scaltriti M; Nuciforo P; Bradbury I; Sperinde J; Agbor-Tarh D; Campbell C; Chenna A; Winslow J; Serra V; Parra JL; Prudkin L; Jimenez J; Aura C; Harbeck N; Pusztai L; Ellis C; Eidtmann H; Arribas J; Cortes J; de Azambuja E; Piccart M; Baselga J
Clin Cancer Res; 2015 Feb; 21(3):569-76. PubMed ID: 25467182
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
[TBL] [Abstract][Full Text] [Related]
9. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
Montemurro F; Prat A; Rossi V; Valabrega G; Sperinde J; Peraldo-Neia C; Donadio M; Galván P; Sapino A; Aglietta M; Baselga J; Scaltriti M
Mol Oncol; 2014 Feb; 8(1):20-6. PubMed ID: 24075779
[TBL] [Abstract][Full Text] [Related]
10. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
[TBL] [Abstract][Full Text] [Related]
11. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Filipits M; Dafni U; Gnant M; Polydoropoulou V; Hills M; Kiermaier A; de Azambuja E; Larsimont D; Rojo F; Viale G; Toi M; Harbeck N; Prichard KI; Gelber RD; Dinh P; Zardavas D; Leyland-Jones B; Piccart-Gebhart MJ; Dowsett M;
Clin Cancer Res; 2018 Jul; 24(13):3079-3086. PubMed ID: 29530933
[No Abstract] [Full Text] [Related]
12. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
13. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Han SW; Cha Y; Paquet A; Huang W; Weidler J; Lie Y; Sherwood T; Bates M; Haddad M; Park IH; Oh DY; Lee KS; Im SA; Bang YJ; Ro J; Kim TY
PLoS One; 2012; 7(7):e39943. PubMed ID: 22848366
[TBL] [Abstract][Full Text] [Related]
14. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
15. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab.
Duchnowska R; Sperinde J; Czartoryska-Arłukowicz B; Myśliwiec P; Winslow J; Radecka B; Petropoulos C; Demlova R; Orlikowska M; Kowalczyk A; Lang I; Ziółkowska B; Dębska-Szmich S; Merdalska M; Grela-Wojewoda A; Żawrocki A; Biernat W; Huang W; Jassem J
Oncotarget; 2017 Nov; 8(61):104149-104159. PubMed ID: 29262628
[TBL] [Abstract][Full Text] [Related]
17. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
19. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.
Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V
Breast Cancer Res; 2015 Aug; 17(1):113. PubMed ID: 26285572
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
